Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia
|
Supraventricular tachycardia Microchapters |
|
Differentiating Among the Different Types of Supraventricular Tachycardia |
|---|
|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
|
Diagnosis |
|
Treatment |
|
2015 ACC/AHA Guideline Recommendations |
|
Case Studies |
|
Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia On the Web |
|
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia |
|
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT. Oral verapamil or diltiazem is reasonable for ongoing management in patients with recurrent symptomatic MAT.[1]
Management of Multifocal Atria Tachycardia
2015 AHA recommendations for the acute and ongoing management of multifocal atrial tachycardia are described below:[1]
Acute treatment of Multifocal Atria Tachycardia
| Class IIa |
| "1.Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT."(Level of Evidence: C-LD) " |
Management of ongoing Multifocal Atria Tachycardia
| Class IIa |
| "1.Oral verapamil "(Level of Evidence: B-NR) " or diltiazem "(Level of Evidence: C-LD) " is reasonable for ongoing management in patients with recurrent symptomatic MAT"(Level of Evidence:B-NR, C-LD) " |
| "2.Metoprolol is reasonable for ongoing management in patients with recurrent symptomatic MAT ( "(Level of Evidence: C-LD) " |
References
- ↑ 1.0 1.1 Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ; et al. (2016). "2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol. 67 (13): e27–e115. doi:10.1016/j.jacc.2015.08.856. PMID 26409259.